Chromothripsis in acute myeloid leukemia: biological features and impact on survival

Leukemia
Maria Chiara FontanaGiovanni Martinelli

Abstract

Chromothripsis is a one-step genome-shattering catastrophe resulting from disruption of one or few chromosomes in multiple fragments and consequent random rejoining and repair. This study defines incidence of chromothripsis in 395 newly diagnosed adult acute myeloid leukemia (AML) patients from three institutions, its impact on survival and its genomic background. SNP 6.0 or CytoscanHD Array (Affymetrix®) were performed on all samples. We detected chromothripsis with a custom algorithm in 26/395 patients. Patients harboring chromothripsis had higher age (p = 0.002), ELN high risk (HR) (p < 0.001), lower white blood cell (WBC) count (p = 0.040), TP53 loss, and/or mutations (p < 0.001) while FLT3 (p = 0.025), and NPM1 (p = 0.032) mutations were mutually exclusive with chromothripsis. Chromothripsis-positive patients showed a worse overall survival (OS) (p < 0.001) compared with HR patients (p = 0.011) and a poor prognosis in a COX-HR optimal regression model. Chromothripsis presented the hallmarks of chromosome instability [i.e., TP53 alteration, 5q deletion, higher mean of copy number alteration (CNA), complex karyotype, alterations in DNA repair, and cell cycle] and focal deletions on chromosomes 4, 7, 12, 16, and 17. CBA. FISH...Continue Reading

References

Jun 23, 2009·Genome Research·Martin KrzywinskiMarco A Marra
Jan 11, 2011·Cell·Matthew Meyerson, David Pellman
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph RölligGerhard Ehninger
Dec 20, 2011·American Journal of Hematology·Elihu H Estey
Mar 19, 2013·Cell·Jan O Korbel, Peter J Campbell
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Dec 5, 2013·Cell Cycle·Guo LiuHenry H Heng
Dec 7, 2013·Current Opinion in Oncology·Wigard P KloostermanJan J Molenaar
Mar 22, 2014·BMC Bioinformatics·Shaylan K GovindPaul C Boutros
Jun 17, 2014·Urologic Oncology·María A Tapia-LalienaStefan Duensing
Jul 12, 2014·BMC Genomics·Ewa PrzybytkowskiMark Basik
Oct 30, 2014·Nature Communications·Katia NonesAndrew P Barbour
May 29, 2015·Nature·Cheng-Zhong ZhangDavid Pellman
Aug 28, 2015·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Birgitte BertelsenZeynep Tümer
Sep 30, 2015·Molecular Systems Biology·Balca R MardinJan O Korbel
Oct 8, 2015·Annual Review of Genetics·Mitchell L LeibowitzDavid Pellman
Dec 15, 2015·Nucleic Acids Research·Antonio FabregatPeter D'Eustachio
Dec 22, 2015·Cell·John MaciejowskiTitia de Lange
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Jan 26, 2017·Blood·Tilmann BochtlerUNKNOWN Study Alliance Leukemia Investigators
Mar 31, 2017·Journal of Hematology & Oncology·A Ghelli Luserna di Rora'G Martinelli

❮ Previous
Next ❯

Citations

Sep 6, 2020·Genome Research·Sergey Aganezov, Benjamin J Raphael
Nov 28, 2019·Journal of Hematology & Oncology·Andrea Ghelli Luserna di RoràGiorgia Simonetti
May 10, 2020·Nature Communications·Natalia VoroninaAurélie Ernst
Jul 25, 2020·European Journal of Haematology·Kyoko FuseMasayoshi Masuko
Feb 26, 2019·Molecular Cytogenetics·Franck Pellestor
Nov 11, 2020·Epigenetics & Chromatin·Wen-Jun WangJiu-Wei Cui
Sep 26, 2020·Cancer Research·Michiel BolkesteinAurélie Ernst
Feb 17, 2021·Seminars in Cell & Developmental Biology·Milena Simovic, Aurélie Ernst
Apr 16, 2020·Trends in Genetics : TIG·Kez Cleal, Duncan M Baird
Feb 26, 2021·Frontiers in Oncology·Matteo MolicaPaolo de Fabritiis
Feb 21, 2021·Seminars in Cell & Developmental Biology·F PellestorV Gatinois
Nov 24, 2018·Best Practice & Research. Clinical Haematology·John S Welch
May 2, 2021·International Journal of Cancer. Journal International Du Cancer·Thorsten Kolb, Aurélie Ernst
Jun 3, 2021·Cells·Mariia ShorokhovaTatiana Grinchuk
May 25, 2021·Blood Cancer Discovery·Emily Schwenger, Ulrich Steidl
Jun 3, 2021·Cancers·Mateus de Oliveira LisboaSabine Mai
Jul 8, 2021·Cancer Discovery·Emily Schwenger, Ulrich Steidl
Aug 29, 2021·Nature Communications·Kylee H MaclachlanFrancesco Maura

❮ Previous
Next ❯

Software Mentioned

CTLP
REACTOME
REDCap
Rawcopy
CTLP scanner
Scanner
R

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.